Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Boehringer Ingelheim awards milestone payment to Xencor

Boehringer Ingelheim awards milestone payment to Xencor

13 Oct 2010
Immunomedics receives additional patent claims for antibody therapy

Immunomedics receives additional patent claims for antibody therapy

13 Oct 2010
First presentation of anti-HER2 antibody-drug conjugate as first-line therapy for advanced breast cancer

First presentation of anti-HER2 antibody-drug conjugate as first-line therapy for advanced breast cancer

12 Oct 2010
Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

12 Oct 2010
Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

12 Oct 2010
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

11 Oct 2010
Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

11 Oct 2010
Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

11 Oct 2010
Combination of MET and erlotinib delays lung cancer progression: Study

Combination of MET and erlotinib delays lung cancer progression: Study

11 Oct 2010
Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

11 Oct 2010
Seattle Genetics reports SGN-75 phase I clinical trial data

Seattle Genetics reports SGN-75 phase I clinical trial data

11 Oct 2010
Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

11 Oct 2010
Role of TGF-ß in cancer diseases

Role of TGF-ß in cancer diseases

7 Oct 2010
Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

7 Oct 2010
Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

6 Oct 2010
Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

6 Oct 2010
Amgen to present oncology portfolio results at ESMO Congress

Amgen to present oncology portfolio results at ESMO Congress

6 Oct 2010
New approach method could simplify study and treatment of human diseases

New approach method could simplify study and treatment of human diseases

6 Oct 2010
Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

5 Oct 2010
Merck Serono to present Erbitux data at ESMO Congress

Merck Serono to present Erbitux data at ESMO Congress

5 Oct 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback